Assessing Outcomes from the EXTEND Clinical Trial Using the Modified Multiplier of the Simple Endoscopic Score for Crohn's disease (MM-SES-CD)

This research study aims to evaluate the ability of the Modified Multiplier of the Simple Endoscopic Score for Crohn's Disease (MM-SES-CD) to assess treatment outcomes in patients with Crohn's Disease (CD). CD is a type of inflammatory bowel disease and can impact any part of the gastrointestinal tract, although it often affects the ileum (e.g. the last part of the small intestine) and colon (e.g. the large intestine). CD patients typically experience symptoms like abdominal pain, weight loss, and diarrhea. The EXTEND trial (NCT00348283) was a study of adalimumab compared to placebo which assessed for endoscopic healing with anti-tumour necrosis factors (anti-TNF) therapy. Adalimumab is a biologic medication that targets and inhibits tumor necrosis factor-alpha (TNF-α), a pro-inflammatory cytokine involved in systemic inflammation. It is a monoclonal antibody that is widely used to treat various autoimmune and inflammatory conditions, including IBD. A significant difference between the continuous drug arm and the placebo arm was not detected by week 12 of the trial and the primary endpoint of endoscopic remission as measured by the SES-CD (Simple Endoscopic Score for Crohn's Disease) was not met. SES-CD is a simpler, more rapid endoscopic scoring system for Crohn's disease. The SES-CD, as its name suggests, is a simpler form to measure healing using using endoscopic evaluation and the more recent MM-SES CD is potentially more accurate.Our hypothesis is that use of the MM-SES-CD instead of the SES-CD may have allowed for higher differentiation compared to placebo, which could have implications for this trial and future clinical trials of Crohn’s disease. The data is intended to assess whether or not the MM-SES-CD is more sensitive than SES-CD.
Impact on Patients: For patients with CD, accurate assessment of treatment efficacy is crucial for effective disease management. If the MM-SES-CD proves to be more sensitive than the traditional SES-CD, it could impact how treatments are evaluated. More accurate detection of treatment benefits means that patients could receive more effective therapies, tailored to their specific condition, leading to better disease control and improved quality of life. The MM-SES-CD could also help in the development of new treatments by providing more precise measurements of their effectiveness during clinical trials. Ultimately, this research could lead to more informed treatment decisions, optimized therapy regimens, and better long-term health outcomes for patients with CD.